Ingredion offers substantial five-year re-rating potential as Tate & Lyle and specialty-ingredient growth transform a discounted wet miller into a higher-margin solutions provider.
Overview
Ingredion is a global ingredient-solutions provider serving CPG, food manufacturing, beverage, and industrial customers with starches, sweeteners, texturizers, and plant proteins. Its strategic evolution is from a commodity-oriented wet miller toward a specialty solutions platform, anchored by T&HS and the proposed £2.7 billion Tate & Lyle acquisition. The company benefits from specified-in formulations, co-creation application labs, proprietary processing technologies, and localized manufacturing, with more than 80% of products made and sold locally. Q2 2026 revenue was $1.85 billion, up 0.93% year over year and above the $1.83 billion consensus, while adjusted EPS of $2.82 exceeded the $2.71–$2.78 estimate range. Reported results were pressured by $45 million of restructuring and impairment costs, the Argo plant fire, Thai tapioca inflation, and a $47 million FX hedging loss. **Management reaffirmed adjusted 2026 EPS guidance of $10.30–$10.90**, with $700–$800 million of operating cash flow and $450–$490 million of capex. At approximately $105.20, the stock trades near a 9.6x trailing P/E and 6.5x–7.5x EV/EBITDA, leaving substantial upside if integration, deleveraging, and specialty-margin expansion support re-rating.